首页> 外文期刊>Pathology oncology research: POR >Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population
【24h】

Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population

机译:希腊人群中乳头状甲状腺癌中的Tert启动子,BRAF和RAS突变的低患病率

获取原文
           

摘要

Thyroid cancer is a common endocrine malignancy and displays a variety of histological patterns ranging from adenoma to malignant tumors. Molecular diagnostics have given significant insights into the genetic basis of thyroid tumorigenesis, known to be linked with signaling pathways affected by oxidative stress. We report for the first time a genotype study of TERT promoter combined with BRAF and RAS mutations in Papillary Thyroid Cancer (PTC) cases in the Greek population. Polymerase Chain Reaction and sequencing were used to identify TERT promoter (C228T, C250T, CC243-243TT) mutations, the BRAF (T1799A) mutation and mutations in codons 12, 13, 61 of the HRAS, KRAS and NRAS genes. The most common C228T TERT promoter mutation was identified in 2 PTC cases co-existing with the BRAF mutation. The BRAF T1799A mutation was detected in 10 PTC cases, while two different NRAS mutations in codon 61 (C181A and A182G) were found in 2 PTC cases. These mutations occur in a mutually exclusive manner. Our results indicate that despite the low frequencies, the study of the specific mutations should be encouraged because they are indicative of aggressive forms of thyroid cancer of the papillary histotype in this patient cohort, thus providing insights towards their therapeutic management.
机译:甲状腺癌是一种常见的内分泌恶性肿瘤,并显示出各种组织学模式,从腺瘤到恶性肿瘤。分子诊断已经对甲状腺肿瘤发生的遗传基础进行了显着的见解,已知与受氧化应激影响的信号传导途径连接。我们首次报告了TERT启动子的基因型研究与希腊人群中乳头状甲状腺癌(PTC)病例中的BRAF和RAS突变结合在一起。聚合酶链反应和测序用于鉴定HRA,KRAS和NRA基因的密码子12,13,61中的TERT启动子(C228T,C250T,CC243-243TT)突变,BRAF(T1799A)突变和突变。在与BRAF突变共存的2个PTC病例中鉴定了最常见的C228T TERT启动子突变。在10个PTC病例中检测到BRAF T1799A突变,而在2个PTC病例中发现了密码子61(C181A和A182G)中的两种不同的NRAS突变。这些突变以互斥的方式发生。我们的结果表明,尽管频率低,但应鼓励对特定突变的研究,因为它们表明该患者群组中乳头状组型的富含甲状腺癌的侵袭性形式,从而为其治疗管理提供了见解。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号